list of glp-1 receptor agonist Comparing Ozempic, Wegovy and Other Drugs Benefits and Risks of GLP-1

In the first 30 days alone, the average Allurion patient already sees 7% body weight loss 10 and achieves 10-15% weight loss in approximately 4 months

Muscle loss slows your metabolism and makes weight regain more likely

Semaglutide has randomized trial evidence in nonalcoholic steatohepatitis demonstrating improvement in key disease activity outcomes. Tirzepatide also has randomized trial evidence in metabolic dysfunctionassociated steatohepatitis (MASH) with liver fibrosis, supporting improvements in steatohepatitis-related endpoints. Clinical takeaway: GLP-1 and GLP-1/GIP therapies can reduce liver fat and liver injury activity in metabolic liver disease settings., 3) They Improve Cardiometabolic Risk Factors That Overlap With Vascular Inflammation Vascular inflammation is an umbrella term

[DOI] [PMC free article] [PubMed] [Google Scholar] 4.Shetty R., Basheer F.T., Poojari P.G., Thunga G., Chandran V.P., Acharya L.D

In fact, although diabetes is the main cause for end-stage kidney disease (ESKD) worldwide, many people with T2D die from CVD before reaching ESKD [2]

The review also noted that decreased GLP-1 secretion may contribute to obesity development, and that exaggerated secretion may be responsible for postprandial reactive hypoglycaemia